FDA sounds the alarm on Pfizer’s blockbuster Xeljanz after a high dose was linked to a higher death rate, blood clots
The FDA is sounding a formal warning about the potential safety hazard posed by a high dose of Pfizer’s blockbuster Xeljanz, taking a move that could put a serious crimp in its blockbuster sales revenue.
Their statement today includes:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.